| Published Version Download ( PDF | 3MB) | License: Creative Commons Attribution 4.0 |
Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
Article
Lippl, Jonas, Reinke, Sarah
, Koch, Karoline, Oschlies, Ilske, Schrod, Stefan, Wolfseher, Lukas, Hüttl, Paul
, Huttner, Michael
, Beà, Silvia, Campo, Elias, Ladetto, Marco, Cogliatti, Sergio, Ehinger, Mats, Rymkiewicz, Grzegorz, Tabanelli, Valentina, Rauert-Wunderlich, Hilka, Rosenwald, Andreas, Spang, Rainer
, Hoster, Eva, Dreyling, Martin, Altenbuchinger, Michael, Klapper, Wolfram, Pott, Christiane, Klener, Pavel, Jerkeman, Mats, Hess, Georg, Cordero, Francesca, Ek, Sara, Ferrero, Simone and Ginè, Eva
(2026)
Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.
Leukemia.
DOI to cite this document: 10.5283/epub.80296
Abstract
The clinical course of Mantle Cell Lymphoma (MCL) varies between individual patients. Early detection of risk is crucial to assign MCL patients to novel treatment strategies. Most of the established biomarkers of outcome require specifically trained pathologists or molecular analysis. Here we introduce MAIPI (MCL Artificial Intelligence Prognostic Index), a deep learning algorithm trained only on ...
The clinical course of Mantle Cell Lymphoma (MCL) varies between individual patients. Early detection of risk is crucial to assign MCL patients to novel treatment strategies. Most of the established biomarkers of outcome require specifically trained pathologists or molecular analysis. Here we introduce MAIPI (MCL Artificial Intelligence Prognostic Index), a deep learning algorithm trained only on Hematoxylin and Eosin (H&E) images of diagnostic biopsies of n = 428 MCL patients from clinical trials to assess prognosis. The capability of MAIPI to predict disease outcome was validated in an independent cohort of n = 140 patients treated with immunochemotherapy with and without ibrutinib. MAIPI selects areas of interest by itself and provides prognostic information independent of the MCL International Prognostic Index (MIPI) and Ki67 and without the need of molecular testing or expert pathologists evaluation.
Involved Institutions
Details
| Item type | Article | ||||||
| Journal or Publication Title | Leukemia | ||||||
| Publisher | Springer Nature | ||||||
| Open Access Type | DEAL (Springer) - Non UR | ||||||
| Date | 7 July 2026 | ||||||
| Date of publication | 05 Aug 2026 08:50 | ||||||
| Institutions | Medicine > Institut für Funktionelle Genomik > Lehrstuhl für Funktionelle Genomik (Prof. Oefner) Medicine > Institut für Funktionelle Genomik > Lehrstuhl für Statistische Bioinformatik (Prof. Spang) Informatics and Data Science > Department Computational Life Science > Lehrstuhl für Statistische Bioinformatik (Prof. Spang) Informatics and Data Science > Department Computational Life Science | ||||||
| Projects |
Funded by:
Bundesministerium für Bildung und Forschung (BMBF)
(01KD2209A)
| ||||||
| Identification Number |
| ||||||
| Dewey Decimal Classification | 000 Computer science, information & general works > 004 Computer science 600 Technology > 610 Medical sciences Medicine | ||||||
| Status | Published | ||||||
| Refereed | Yes, this version has been refereed | ||||||
| Created at the University of Regensburg | Partially | ||||||
| URN of the UB Regensburg | urn:nbn:de:bvb:355-epub-802963 | ||||||
| Item ID | 80296 |
Download Statistics
Download Statistics